SCHEMBL396567

SCHEMBL396567

NC(C(F)(F)F)C(F)(F)F

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CETP P11597 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7746748 0.76 ALDH1A1 (0.32) ALDH1A1HSD17B10
SCHEMBL18306044 0.76
SCHEMBL12364122 0.76
SCHEMBL18305963 0.76
SCHEMBL18351724 0.74
SCHEMBL28765168 0.73
Hydrochloric Acid SCHEMBL20531828 0.73
Hydrochloric Acid SCHEMBL20531826 0.73
SCHEMBL13112936 0.71
SCHEMBL14972912 0.70 CETP (0.32) CETPALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161911-A1 POLYMERS FOR THE REMOVAL OF PFAS FROM AQUEOUS COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME GULF COAST ENVIRONMENTAL SYSTEMS LLC (DBA CONIFER SYSTEMS) 2025-05-22 US claimed
WO-2025106778-A1 POLYMERS FOR THE REMOVAL OF PFAS FROM AQUEOUS COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME LUTUM TECHNOLOGY, LLC (US) 2025-05-22 WO claimed
CN-113861688-B Low-dielectric polyphenylene sulfide composite material and preparation method thereof 江西聚真科技发展有限公司 2022-09-16 CN claimed
WO-2022191429-A1 METHOD FOR ETCHING MULTI-LAMINATE OF SILICON-CONTAINING FILMS, AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE, COMPRISING SAME 에스케이 머티리얼즈 주식회사 2022-09-15 WO claimed
CN-113861688-A Low-dielectric polyphenylene sulfide composite material and preparation method thereof 江西聚真科技发展有限公司 2021-12-31 CN claimed
US-9879293-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2018-01-30 US claimed
US-20160177354-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS SAFC, INC. 2016-06-23 US claimed
EP-2462115-B1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS INC (US) 2016-01-06 EP claimed
US-8703448-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2014-04-22 US claimed
EP-2462115-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS Infinity Pharmaceuticals, Inc. (US) 2012-06-13 EP claimed
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs INFINITY PHARMACEUTICALS, INC. (US) 2012-04-05 US claimed
WO-2011017551-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 WO claimed
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US claimed
EP-0772601-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-05-14 EP claimed
WO-2025106778-A1 POLYMERS FOR THE REMOVAL OF PFAS FROM AQUEOUS COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME LUTUM TECHNOLOGY, LLC (US) 2025-05-22 WO disclosed
US-20250161911-A1 POLYMERS FOR THE REMOVAL OF PFAS FROM AQUEOUS COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME GULF COAST ENVIRONMENTAL SYSTEMS LLC (DBA CONIFER SYSTEMS) 2025-05-22 US disclosed
EP-4541422-A2 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS Gilead Sciences, Inc. (US) 2025-04-23 EP disclosed
EP-0155423-A2 Heat pumps IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-09-25 EP disclosed
US-4541943-A FLUOROCARBON, FLUOROCARBON ETHER OR FLUOROALKYLAMINE FLUIDS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-09-17 US disclosed
EP-0127365-A2 Heat pumps IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 CETP 2555/4885ALDH1A1 112/4885HSD17B10 184/4885
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs TKT, TALDO1, BCHE CETP 1037/4885ALDH1A1 693/4885HSD17B10 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.